首页> 外文期刊>Trials >Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease
【24h】

Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease

机译:肾脏病学的标准化结果—多囊肾(SONG-PKD):建立多囊肾疾病核心结局的研究方案

获取原文
           

摘要

Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening inherited kidney disease and is responsible for 5–10% of cases of end-stage kidney disease (ESKD). Cystic kidneys may enlarge up to 20 times the weight of a normal kidney due to the growth of renal cysts, and patients with ADPKD have an increased risk of morbidity, premature mortality, and other life-time complications including renal and hepatic cyst and urinary tract infection, intracranial aneurysm, diverticulosis, and kidney pain which impair quality of life. Despite some therapeutic advances and the growing number of clinical trials in ADPKD, the outcomes that are relevant to patients and clinicians, such as symptoms and quality of life, are infrequently and inconsistently reported. This potentially limits the contribution of trials to inform evidence-based decision-making. The Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD) project aims to establish a consensus-based set of core outcomes for trials in PKD (with an initial focus on ADPKD but inclusive of all stages) that patients and health professionals identify as critically important. The five phases of SONG-PKD are: a systematic review to identify outcomes that have been reported in existing PKD trials; focus groups with nominal group technique with patients and caregivers to identify, rank, and describe reasons for their choices; qualitative stakeholder interviews with health professionals to elicit individual values and perspectives on outcomes for trials involving patients with PKD; an international three-round Delphi survey with all stakeholder groups (including patients, caregivers, healthcare providers, policy makers, researchers, and industry) to gain consensus on critically important core outcome domains; and a consensus workshop to review and establish a set of core outcome domains and measures for trials in PKD. The SONG-PKD core outcome set is aimed at improving the consistency and completeness of outcome reporting across ADPKD trials, leading to improvements in the reliability and relevance of trial-based evidence to inform decisions about treatment and ultimately improve the care and outcomes for people with ADPKD.
机译:常染色体显性遗传性多囊肾病(ADPKD)是最常见的潜在威胁生命的遗传性肾病,占终末期肾脏病(ESKD)病例的5-10%。由于肾囊肿的增长,囊性肾脏的重量可能会增加至正常肾脏重量的20倍,ADPKD患者的发病率,过早死亡以及其他终生并发症(包括肾,肝囊肿和尿路)的风险增加感染,颅内动脉瘤,憩室病和肾痛会损害生活质量。尽管在ADPKD中取得了一些治疗进展和临床试验,但与患者和临床医生相关的结果(例如症状和生活质量)却很少且不一致地报道。这可能会限制试验在为基于证据的决策提供依据方面的贡献。肾脏病标准化结果-多囊肾病(SONG-PKD)项目旨在为患者和卫生专业人员确定的PKD试验建立一套基于共识的核心结果(最初侧重于ADPKD,但包括所有阶段)至关重要。 SONG-PKD的五个阶段是:对现有PKD试验中已报告的结局进行系统评价;以名义分组技术对患者和照顾者进行分组,以识别,排序和描述他们选择的原因;与卫生专业人员进行定性利益相关者访谈,以得出涉及PKD患者的试验的个人价值和对结果的看法;对所有利益相关者群体(包括患者,护理人员,医疗保健提供者,决策者,研究人员和行业)进行的国际Delphi三轮调查,以在至关重要的核心结果领域上达成共识;召开共识研讨会,审查并建立一套核心结果领域和公钥簿试验方法。 SONG-PKD核心结果集旨在改善整个ADPKD试验结果报告的一致性和完整性,从而改善基于试验的证据的可靠性和相关性,从而为治疗决策提供依据,并最终改善患有以下疾病的人的护理和结果ADPKD。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号